BR112022012110A2 - Compostos e métodos para a degradação direcionada de receptor androgênico - Google Patents
Compostos e métodos para a degradação direcionada de receptor androgênicoInfo
- Publication number
- BR112022012110A2 BR112022012110A2 BR112022012110A BR112022012110A BR112022012110A2 BR 112022012110 A2 BR112022012110 A2 BR 112022012110A2 BR 112022012110 A BR112022012110 A BR 112022012110A BR 112022012110 A BR112022012110 A BR 112022012110A BR 112022012110 A2 BR112022012110 A2 BR 112022012110A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- methods
- androgen receptor
- receptor degradation
- targeted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
SISTEMA DE FLUIDO DE UMA AERONAVE, E AERONAVE. Esta divulgação refere-se a compostos, sua preparação e ao uso desses compostos no tratamento de câncer de próstata, incluindo câncer de próstata metastático e/ou resistente à castração, em sujeitos em necessidade.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962950815P | 2019-12-19 | 2019-12-19 | |
US202063032473P | 2020-05-29 | 2020-05-29 | |
US202063089497P | 2020-10-08 | 2020-10-08 | |
PCT/US2020/066021 WO2021127443A1 (en) | 2019-12-19 | 2020-12-18 | Compounds and methods for the targeted degradation of androgen receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022012110A2 true BR112022012110A2 (pt) | 2022-12-13 |
Family
ID=74195122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022012110A BR112022012110A2 (pt) | 2019-12-19 | 2020-12-18 | Compostos e métodos para a degradação direcionada de receptor androgênico |
Country Status (18)
Country | Link |
---|---|
US (1) | US11883393B2 (pt) |
EP (1) | EP4077309A1 (pt) |
JP (1) | JP2023507570A (pt) |
KR (1) | KR20220119094A (pt) |
CN (1) | CN115175901B (pt) |
AU (1) | AU2020405129A1 (pt) |
BR (1) | BR112022012110A2 (pt) |
CA (1) | CA3165168A1 (pt) |
CL (1) | CL2022001662A1 (pt) |
CO (1) | CO2022008728A2 (pt) |
CR (1) | CR20220353A (pt) |
DO (1) | DOP2022000128A (pt) |
EC (1) | ECSP22055515A (pt) |
IL (1) | IL293961A (pt) |
MX (1) | MX2022007678A (pt) |
PE (1) | PE20221582A1 (pt) |
TW (1) | TW202136240A (pt) |
WO (1) | WO2021127443A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220008869A (ko) | 2019-05-14 | 2022-01-21 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체-표적화 화합물 |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
IL306010A (en) | 2021-03-23 | 2023-11-01 | Nuvation Bio Inc | Anticancer compounds against the nuclear hormone receptor |
TW202329950A (zh) * | 2021-11-25 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種用於雄激素受體蛋白靶向降解的嵌合體化合物、其製備方法及其在醫藥上的應用 |
WO2024054955A1 (en) * | 2022-09-08 | 2024-03-14 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and methods of treating disease |
Family Cites Families (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2460304C2 (de) | 1974-12-20 | 1983-08-04 | Grünenthal GmbH, 5190 Stolberg | 1-n-Propyl-4-phthalimido-piperidin-2,6-dion, Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5510357A (en) | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
CA2624949C (en) | 1996-07-24 | 2011-02-15 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels |
JP4903922B2 (ja) | 1997-05-14 | 2012-03-28 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 選択された蛋白質を分解する複合化合物 |
WO1999015521A1 (en) | 1997-09-23 | 1999-04-01 | Eli Lilly And Company | Benzothiophenes |
WO1999031061A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
US6525072B1 (en) | 1998-08-31 | 2003-02-25 | Sugen, Inc. | Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity |
US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
ES2257296T3 (es) | 1999-05-05 | 2006-08-01 | MERCK & CO., INC. | Nuevas prolinas como agentes antimicrobianos. |
EP1299094A2 (en) | 2000-06-28 | 2003-04-09 | Bristol-Myers Squibb Company | Selective androgen receptor modulators and methods for their identification, design and use |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
US7041298B2 (en) | 2000-09-08 | 2006-05-09 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
JP2005507363A (ja) | 2001-02-16 | 2005-03-17 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 血管新生阻害トリペプチド、組成物およびそれらの使用方法 |
GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
HN2002000136A (es) | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
DE60331537D1 (de) | 2002-05-17 | 2010-04-15 | Celgene Corp | Kombinationen zur behandlung von multiplem myelom |
MXPA05001536A (es) | 2002-08-30 | 2005-04-19 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
DE602004025708D1 (de) | 2003-07-11 | 2010-04-08 | Proteologics Inc | Ubiquitin-ligase-hemmer und verwandte verfahren |
JP4874965B2 (ja) | 2004-07-08 | 2012-02-15 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | アンドロゲン調節剤 |
CN100383139C (zh) | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2,6-二酮衍生物 |
WO2006113942A2 (en) | 2005-04-20 | 2006-10-26 | Schering Corporation | Method of inhibiting cathepsin activity |
PE20070100A1 (es) | 2005-06-22 | 2007-03-10 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO MODULADORES DE QUINASAS |
ZA200802490B (en) | 2005-08-31 | 2009-10-28 | Celgene Corp | Isoindole-imide compounds and compositions comprising and methods of using the same |
US20090062537A1 (en) | 2006-03-03 | 2009-03-05 | Kwangho Lee | N-Formyl Hydrozyamine Compounds |
RU2449993C2 (ru) | 2006-03-29 | 2012-05-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Диарилтиогидантоиновые соединения |
JP2009544620A (ja) | 2006-07-20 | 2009-12-17 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 自己免疫疾患及び炎症のためのプロリン尿素ccr1アンタゴニスト |
CA2660806C (en) | 2006-08-30 | 2015-06-16 | Celgene Corporation | 5-substituted isoindoline compounds |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
RU2448101C2 (ru) | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-замещенные изоиндолиновые соединения |
ES2403546T3 (es) | 2006-11-03 | 2013-05-20 | Pharmacyclics, Inc. | Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización |
WO2008087643A2 (en) | 2007-01-16 | 2008-07-24 | Proteologics Ltd | Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors |
ES2392003T3 (es) | 2007-07-25 | 2012-12-03 | Bristol-Myers Squibb Company | Inhibidores de la triazina quinasa |
EP2175726A4 (en) | 2007-07-31 | 2011-01-05 | Androscience Corp | COMPOSITIONS WITH ANDROGEN RECEPTOR DERIVATIVES AND METHOD FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF SKIN DISEASES OR HAIR LOSS |
WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
KR20180000750A (ko) | 2008-10-29 | 2018-01-03 | 셀진 코포레이션 | 암의 치료에 사용하기 위한 이소인돌린 화합물 |
US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
WO2010141805A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
BR112012000867A2 (pt) | 2009-07-13 | 2019-09-24 | Harvard College | "polipeptídeos bifuncional costurado e uso do mesmo" |
EP4289838A3 (en) | 2010-02-11 | 2024-03-13 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
US8198300B2 (en) | 2010-04-29 | 2012-06-12 | Universidad De Chile | Method for preventing tau protein aggregation and treating Alzheimer's disease with a quinoline derivative compound |
ES2534521T3 (es) | 2010-05-14 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Composiciones y su uso en el tratamiento de neoplasia, enfermedades inflamatorias y otras enfermedades |
AU2011252799B2 (en) | 2010-05-14 | 2015-05-14 | Cold Spring Harbor Laboratory | Compositions and methods for treating leukemia |
US20180144649A1 (en) | 2010-06-07 | 2018-05-24 | Affectiva, Inc. | Smart toy interaction using image analysis |
US9765019B2 (en) | 2010-06-30 | 2017-09-19 | Brandeis University | Small-molecule-targeted protein degradation |
US8822520B2 (en) | 2010-09-22 | 2014-09-02 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
CN103261169A (zh) | 2010-09-24 | 2013-08-21 | 密歇根大学董事会 | 脱泛素酶抑制剂及其应用方法 |
CN102477033A (zh) | 2010-11-23 | 2012-05-30 | 苏州波锐生物医药科技有限公司 | 苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途 |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
EP2649099A4 (en) | 2010-12-07 | 2016-10-19 | Univ Yale | HYDROPHOBIC MARKING OF SMALL MOLECULES OF FUSION PROTEINS AND INDUCED DEGRADATION THEREOF |
US20140243282A1 (en) | 2010-12-31 | 2014-08-28 | Satish Reddy Kallam | Methods and compositions for designing novel conjugate therapeutics |
EP2702410A2 (en) | 2011-04-29 | 2014-03-05 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
HUE029656T2 (en) | 2011-12-31 | 2017-03-28 | Beigene Ltd | Condensed tricyclic compounds as RAF kinase inhibitors |
WO2013106643A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
US20150119435A1 (en) | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
CA2877434A1 (en) | 2012-06-25 | 2014-01-03 | Oncoethix Sa | Method of treating lymphoma using thienotriazolodiazepine compounds |
CA2879454A1 (en) | 2012-07-19 | 2014-01-23 | Drexel University | Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
TWI569799B (zh) | 2012-09-21 | 2017-02-11 | 安羅格製藥股份有限公司 | 抑制組成型活性磷酸化flt3激酶的方法 |
GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
NL2011274C2 (en) | 2013-08-06 | 2015-02-09 | Illumicare Ip B V 51 | Groundbreaking platform technology for specific binding to necrotic cells. |
WO2014128111A1 (de) | 2013-02-22 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | 4-substituierte pyrrolo- und pyrazolo-diazepine |
US9492460B2 (en) | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
CA2918813A1 (en) | 2013-07-23 | 2015-01-29 | Bayer Pharma Aktiengesellschaft | Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases |
EP3027604B1 (en) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
US20150051208A1 (en) | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
US9428513B2 (en) | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
EP3071203B1 (en) | 2013-11-18 | 2020-12-23 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
US20150259288A1 (en) | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
JP6778114B2 (ja) | 2014-04-14 | 2020-10-28 | アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. | イミド系タンパク質分解モジュレーター及び関連する使用方法 |
TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
WO2015195863A1 (en) | 2014-06-20 | 2015-12-23 | Constellation Pharmaceuticals, Inc. | Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide |
US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
CN106715439A (zh) | 2014-10-02 | 2017-05-24 | 葛兰素史克知识产权第二有限公司 | 化合物 |
EP3212654B1 (en) | 2014-10-27 | 2020-04-08 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
US9845291B2 (en) | 2014-12-18 | 2017-12-19 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
EP3256470B1 (en) | 2014-12-23 | 2023-07-26 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
MX2017009454A (es) | 2015-01-20 | 2017-10-20 | Arvinas Inc | Compuestos y metodos para la degradacion dirigida de receptor de androgenos. |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
GB201504314D0 (en) | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
WO2016149668A1 (en) | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
BR112017025975B1 (pt) | 2015-06-04 | 2023-12-12 | Arvinas Operations, Inc | Composto, composição, método in vitro para induzir degradação de uma proteína alvo em uma célula, e, uso de uma composição |
US20180147202A1 (en) | 2015-06-05 | 2018-05-31 | Arvinas, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
CA2988430A1 (en) | 2015-07-10 | 2017-01-19 | Arvinas, Inc. | Mdm2-based modulators of proteolysis and associated methods of use |
BR112017028269A2 (pt) | 2015-07-13 | 2018-09-04 | Arvinas Inc | composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto. |
EP3331906A1 (en) | 2015-08-06 | 2018-06-13 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
EP3370715A4 (en) | 2015-11-02 | 2019-05-15 | Yale University | CHIMERIC COMPOUNDS PROVIDED AGAINST PROTEOLYSIS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
CA3017740A1 (en) | 2016-03-16 | 2017-09-21 | Pearlie BURNETTE | Small molecules against cereblon to enhance effector t cell function |
US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
RU2021102253A (ru) | 2016-04-06 | 2021-03-03 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Деструкторы белка mdm2 |
WO2017185036A1 (en) | 2016-04-22 | 2017-10-26 | Dana Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
HRP20230414T1 (hr) * | 2016-10-11 | 2023-07-07 | Arvinas Operations, Inc. | Spojevi i postupci za ciljanu razgradnju androgenog receptora |
KR20230127371A (ko) | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
EP3544957A4 (en) | 2016-11-22 | 2020-09-02 | Dana-Farber Cancer Institute, Inc. | KINASE PROTEIN DEGRADATION BY CONJUGATION OF KINASE PROTEIN INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE |
AU2017366693B2 (en) | 2016-12-01 | 2021-04-01 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
WO2018119441A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
IL294423B2 (en) | 2016-12-23 | 2024-01-01 | Univ Yale | Compounds and methods for targeted reduction of rapidly accelerated polypeptide fibrosarcoma |
US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
EP3573977A4 (en) | 2017-01-26 | 2020-12-23 | Arvinas Operations, Inc. | EESTROGEN RECEPTOR PROTEOLYSIS MODULATORS AND RELATED METHOD OF USE |
KR20190116315A (ko) * | 2017-01-31 | 2019-10-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 세레블론 리간드 및 이를 포함하는 이작용성 화합물 |
EP3615083A4 (en) | 2017-04-28 | 2021-05-19 | Zamboni Chem Solutions Inc. | RAF DEGRADATION CONJUGATES |
CA3062161A1 (en) | 2017-05-01 | 2018-11-08 | Spg Therapeutics, Inc. | Tripartite androgen receptor eliminators, methods and uses thereof |
EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE BASED MODULATORS OF PROTEOLYSIS AND METHOD OF USE |
AU2019250361B2 (en) | 2018-04-12 | 2023-03-23 | Bayer Aktiengesellschaft | Heteroaryl-triazole compounds as pesticides |
CN110746399B (zh) | 2018-07-23 | 2022-04-22 | 上海美志医药科技有限公司 | 具有降解雄激素受体活性的化合物 |
SG11202106506WA (en) | 2018-12-19 | 2021-07-29 | Celgene Corp | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
AU2019403207A1 (en) | 2018-12-19 | 2021-07-15 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
US11547759B2 (en) | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
EP3946292A4 (en) | 2019-03-28 | 2023-05-17 | Essa Pharma, Inc. | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE AS ANTI-PROTEOLYTIC CHIMERA LIGANDS |
US20220218632A1 (en) | 2019-03-28 | 2022-07-14 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
US20220220124A1 (en) | 2019-04-18 | 2022-07-14 | Accutar Biotechnology Inc. | Novel compounds having bet, estrogen receptor, and androgen receptor degradation activity and uses thereof |
US20220257774A1 (en) | 2019-05-17 | 2022-08-18 | Hinova Pharmaceuticals Inc. | Aromatic amine ar ahd bet targeting protein degradation chimera compound and use |
US20220380368A1 (en) | 2019-09-19 | 2022-12-01 | The Regents Of The University Of Michigan | Spirocyclic androgen receptor protein degraders |
WO2021061644A1 (en) | 2019-09-23 | 2021-04-01 | Accutar Biotechnology Inc. | Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof |
CA3155290A1 (en) | 2019-09-23 | 2021-04-01 | Accutar Biotechnology Inc. | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof |
EP4034114A4 (en) | 2019-09-23 | 2023-07-26 | Accutar Biotechnology Inc. | NEW UREAES HAVING ANDROGEN RECEPTOR DEGRADING ACTIVITY AND THEIR USES |
CA3165238A1 (en) | 2019-12-19 | 2021-06-24 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
WO2021122415A1 (en) | 2019-12-19 | 2021-06-24 | Bayer Aktiengesellschaft | Furoindazole derivatives |
CA3161108A1 (en) | 2019-12-19 | 2021-06-24 | Vincent Gerusz | Pyrido-azepine compounds and their uses as antibiotics |
BR112022012003A2 (pt) | 2019-12-19 | 2022-08-30 | Skinosive | Compostos fotoprotetores adesivos e usos dos mesmos |
US20230142285A1 (en) | 2019-12-19 | 2023-05-11 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
IL294225A (en) | 2019-12-23 | 2022-08-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | Method of preparation of a protein-degrading agent compound and application |
EP4081521A1 (en) | 2019-12-27 | 2022-11-02 | Lupin Limited | Substituted tricyclic compounds |
CN113582974B (zh) | 2020-04-30 | 2022-05-17 | 江西济民可信集团有限公司 | 一类作为蛋白降解剂的化合物及其制备方法和医药用途 |
MX2022015022A (es) | 2020-05-29 | 2023-03-08 | Blueprint Medicines Corp | Composiciones farmaceuticas de pralsetinib. |
EP4185589A1 (en) | 2020-05-29 | 2023-05-31 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic heterocyclic compounds |
MX2022015562A (es) | 2020-06-12 | 2023-01-30 | Shanghai Jemincare Pharmaceuticals Co Ltd | Compuesto de ftalazinona, y metodo de preparacion y uso medico de este. |
AU2021296833A1 (en) | 2020-06-24 | 2023-01-19 | Celgene Corporation | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
CN113912589B (zh) | 2020-07-08 | 2023-10-20 | 北京泰德制药股份有限公司 | 抑制并诱导蛋白降解的化合物 |
CN114133379B (zh) | 2020-09-04 | 2024-02-13 | 南京奥瑞药业有限公司 | 一种杂环化合物、其制备方法、中间体、组合物以及应用 |
CN114163444B (zh) | 2020-09-11 | 2023-07-14 | 江苏恒瑞医药股份有限公司 | 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用 |
WO2022111526A1 (zh) | 2020-11-25 | 2022-06-02 | 四川海思科制药有限公司 | 一种苯环衍生物及其组合物和药学上的应用 |
-
2020
- 2020-12-18 AU AU2020405129A patent/AU2020405129A1/en active Pending
- 2020-12-18 EP EP20845272.2A patent/EP4077309A1/en active Pending
- 2020-12-18 WO PCT/US2020/066021 patent/WO2021127443A1/en active Application Filing
- 2020-12-18 CA CA3165168A patent/CA3165168A1/en active Pending
- 2020-12-18 MX MX2022007678A patent/MX2022007678A/es unknown
- 2020-12-18 CR CR20220353A patent/CR20220353A/es unknown
- 2020-12-18 US US17/126,501 patent/US11883393B2/en active Active
- 2020-12-18 KR KR1020227024738A patent/KR20220119094A/ko unknown
- 2020-12-18 IL IL293961A patent/IL293961A/en unknown
- 2020-12-18 BR BR112022012110A patent/BR112022012110A2/pt unknown
- 2020-12-18 PE PE2022001136A patent/PE20221582A1/es unknown
- 2020-12-18 JP JP2022537498A patent/JP2023507570A/ja active Pending
- 2020-12-18 TW TW109144990A patent/TW202136240A/zh unknown
- 2020-12-18 CN CN202080092856.XA patent/CN115175901B/zh active Active
-
2022
- 2022-06-17 DO DO2022000128A patent/DOP2022000128A/es unknown
- 2022-06-17 CL CL2022001662A patent/CL2022001662A1/es unknown
- 2022-06-22 CO CONC2022/0008728A patent/CO2022008728A2/es unknown
- 2022-07-15 EC ECSENADI202255515A patent/ECSP22055515A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021127443A1 (en) | 2021-06-24 |
CN115175901B (zh) | 2024-03-22 |
CR20220353A (es) | 2022-10-20 |
CL2022001662A1 (es) | 2023-02-10 |
TW202136240A (zh) | 2021-10-01 |
AU2020405129A1 (en) | 2022-06-23 |
KR20220119094A (ko) | 2022-08-26 |
CO2022008728A2 (es) | 2022-07-19 |
DOP2022000128A (es) | 2022-08-31 |
US11883393B2 (en) | 2024-01-30 |
ECSP22055515A (es) | 2022-09-30 |
PE20221582A1 (es) | 2022-10-06 |
US20210196710A1 (en) | 2021-07-01 |
IL293961A (en) | 2022-08-01 |
CN115175901A (zh) | 2022-10-11 |
CA3165168A1 (en) | 2021-06-24 |
MX2022007678A (es) | 2022-09-19 |
JP2023507570A (ja) | 2023-02-24 |
EP4077309A1 (en) | 2022-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022012110A2 (pt) | Compostos e métodos para a degradação direcionada de receptor androgênico | |
BRPI0816095A2 (pt) | Composto ou um sal do mesmo, pró-droga, agente farmacêutico, métodos para antagonizar um receptor de androgênio e para prevenir / tratar cãncer, e, uso do composto ou uma pró-droga do mesmo. | |
BR112018074922A2 (pt) | agonista de receptores de glucocorticoides e seus imunoconjugados | |
BR112019010943A2 (pt) | métodos para o tratamento do câncer compreendendo agentes de ligação a tigit | |
MX2021008053A (es) | Metodos para monitorear y terapias para usarse en tratar el cancer. | |
BR112017002080A2 (pt) | ?anticorpo monoclonal ou fragmento de ligação, molécula de ácido nucleico isolada, vetor, célula hospedeira, métodos para preparar o anticorpo monoclonal ou fragmento de ligação, in vivo ou in vitro e para prevenção e/ou tratamento e/ou terapia adjuvante e/ou diagnóstico de um tumor, conjugado, kit, uso de um anticorpo monoclonal ou fragmento de ligação, e, composição farmacêutica? | |
ECSP17034845A (es) | Conjugados de anticuerpo- farmaco | |
BR112018006257A2 (pt) | anticorpos anti-pd-1 e composições | |
MX2021005353A (es) | Composiciones, metodos y sistemas para el analisis de la corona proteica y usos de los mismos. | |
BR112018075288A2 (pt) | métodos para diagnóstico de infecções bacterianas e virais | |
BR112017004141B8 (pt) | Agente de imagemamento e seu uso | |
PH12015501744B1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
BR112016017986A2 (pt) | anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos de produção de um anticorpo, de tratamento do câncer, de tratamento de uma doença e de detecção de jagged1 humana em uma amostra biológica, imunoconjugado, formulação farmacêutica e uso do anticorpo | |
EP3847274A4 (en) | METHODS AND SYSTEMS FOR THERAPEUTIC AGENT ANALYSIS | |
CL2016002257A1 (es) | Anticuerpos anti-mcam y métodos de uso asociados | |
EP3490677A4 (en) | LIPID, PROTEIN AND METABOLITE MARKER FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | |
BR112020009759A8 (pt) | Anticorpos específicos para transcrito 3 semelhante à imunoglobulina (ilt3) e usos dos mesmos | |
FR3035521B3 (fr) | Dispositif de securite pour pilote d'avion, ensemble de protection comprenant le dispositif et systeme de protection. | |
BR112021023024A2 (pt) | Anticorpo contra claudina 18a2 e uso do mesmo | |
BR112018076528A2 (pt) | composições e métodos para diagnosticar cânceres de pulmão usando perfis de expressão gênica | |
BR112019005944A2 (pt) | anticorpos que se ligam à interleucina 2 e usos dos mesmos | |
BR112022008558A2 (pt) | Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso | |
BR112019020414A2 (pt) | composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina | |
BR112021023173A2 (pt) | Moléculas de ligação à claudin-6 e usos das mesmas | |
BR112019003712A2 (pt) | composições marcadoras, e métodos para produção e uso das mesmas |